Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community

Journal of Clinical Psychiatry

Volumn 64, Issue 4, 2003, Pages 466-472

  Stahl, Stephen M ^a   Markowitz, Jeffrey S ^b   Gutterman, Elane M ^b   Papadopoulos, George ^c  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b Health Data Analytics   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT; RIVASTIGMINE; TACRINE; TEMAZEPAM; ZOLPIDEM TARTRATE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CAREGIVER; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLEEP DISORDER; SOCIAL PSYCHIATRY; STATISTICAL ANALYSIS; SYMPTOMATOLOGY;

EID: 0037696295     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0418     Document Type: Article

References (38)

1. McCurry SM, Logsdon RG, Teri L, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer disease patients. J Geriatr Psychiatry Neurol 1999;12:53-59
2. Nourhashemi F, Andrieu S, Sastres N, et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:21-25
3. Weiner DK, Hanlon JT, Studenski SA. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology 1998;44:217-221
4. Rogers SL, Doody RS, Mohs RC, et al, Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031
5. Rogers SL, Farlow MR, Doody RS, et al., Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145
6. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244
7. Ross JS, Shua-Haim JR. Aricept-induced nightmares in Alzheimer's disease: 2 case reports. J Am Geriatr Soc 1998;46:119-120
8. Wilkinson D, Passmore P, Potocnik F, et al. Donepezil compared with rivastigmine in Alzheimer's disease: similar efficacy but better tolerability, and physician and caregiver satisfaction in a multinational randomized trial [poster]. Presented at the 14th annual meeting of the American Association of Geriatric Psychiatry; February 23-26, 2001; San Francisco, Calif
9. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65
10. Davis K, Thal L, Gamzu E, et al. and the Tacrine Collaborative Study Group. Tacrine in patients with Alzheimer's disease: a double-blind, placebo-controlled multicenter study. N Engl J Med 1992;327: 1253-1259
11. Farlow M, Gracon S, Hershey L, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;68:2523-2529
12. Knapp M, Knopman D, Solomon P, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
13. Raskind MA, Peskind ER, Wessel T, et al, Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268
14. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;318:633-638
15. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine. Neurology 2000;54:2269-2276
16. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 2000;321:1445-1449
17. Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord 2000;11(supp 11):28-34
18. Buysse DJ, Reynolds III CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr Res 1989;28:193-213
19. Grace JB, Walker MP, McKeith IG. A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000;15:1028-1033
20. Schredl M, Weber B, Braus D, et al. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 2000;35:243-249
21. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 2nd ed. Littleton, Mass: PSG Publishing Co; 1985
22. Stahl SM. Does evidence from clinical trials in psychopharmacology apply in clinical practice? [BRAINSTORMS] J Clin Psychiatry 2001;62:6-7
23. Nelson P. AD diagnosis and treatment guide (updated by Wu E). Alzheimer Research Forum. Available at www.alzforum.org/members/research/ treatment-guide/index.html. Accessed Aug 23, 2001
24. Fillit H, Gutterman EM, Brooks RL. The impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int Psychogeriatr 2000;12:389-401
25. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-850
26. Teri L, Truax P, Logsdon R, et al. Assessment of behavioral problems in dementia: the Revised Memory and Behavior Problems Checklist. Psychol Aging 1992;7:622-631
27. Christos GA. Is Alzheimer's disease related to a deficit or malfunction of rapid eye movement (REM) sleep? Med Hypotheses 1993;41:435-439
28. Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999;22:273-280
29. Moe KE, Vitiello MV, Larsen LH, et al. Cognitive processes and sleep disturbances: sleep/wake patterns in Alzheimer's disease: relationships with cognition and function [symposium]. J Sleep Res 1995;4:15-20
30. Reynolds CF 3rd, Kupfer DJ, Taska LS, et al. EEG sleep in elderly depressed, demented, and healthy subjects. Biol Psychiatry 1985;20: 431-442
31. Vitiello MV, Prinz PN. Alzheimer's disease: sleep and sleep/wake patterns. Clin Geriatr Med 1989;5:289-299
32. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15
33. Gillman PK. Tacrine for treatment of sleep disturbance in dementia [letter]. J Am Geriatr Soc 1997;45:1286
34. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000;55:870-871
35. Sitaram N, Gillin JC. Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness. Biol Psychiatry 1980;15:925-955
36. Zoltoski RK, de Jesus Cabeza R, Gillin JC. Biochemical pharmacology of sleep. In: Chokroverty S, ed. Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects. 2nd ed. Boston, Mass: Butterworth-Heinemann; 1999
37. 1A receptor probes in patients with major depression and in normal controls. Biol Psychiatry 1998;44:21-33
38. Ancoli-Israel S, Klauber MR, Gillin JC, et al. Sleep in noninstitutionalized Alzheimer's disease patients. Aging Clin Exp Res 1994;6:451-458